Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes.
CA Cancer J Clin
; 62(5): 299-308, 2012.
Article
en En
| MEDLINE
| ID: mdl-22535487
ABSTRACT
There have been more drugs approved by the US Food and Drug Administration for the treatment of castration-resistant prostate cancer in the past 3 years than in the prior 3 decades, with additional drugs on the verge of approval based on the results of recently reported randomized trials. While an improvement in the understanding of the pathogenesis of castration-resistant prostate cancer has undeniably accelerated the transition of novel approaches from "bench to bedside," the recent successes in the treatment of prostate cancer are also a result of the efforts of clinical investigators to redefine the framework in which drugs for castration-resistant disease are evaluated. This review will explore the shifting paradigm in drug development for castration-resistant prostate cancer over the past several decades, and highlight how new definitions, trial designs, and endpoints have facilitated the emergence of new therapies for this challenging disease.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Castración
Tipo de estudio:
Clinical_trials
Idioma:
En
Revista:
CA Cancer J Clin
Año:
2012
Tipo del documento:
Article
País de afiliación:
Estados Unidos